peptide regulation in 2026 is a group project where nobody shares the doc. we keep the FDA, HHS and state updates in one place: https://t.co/hLVGT0zrJU
🚨FDA ALERT: FDA is requiring all approved GLP-1 drug labels to add a warning about a potential increased risk of NAION, a rare eye condition that can cause vision loss. Drug Safety Communication dated Nov 9 https://t.co/zhhfu1kMhb
"statistically significant" doesn't mean big, important or proven in people. it means the result probably wasn't chance in that one study's setup. check how large the effect was and what it was measured in
a review paper isn't a new study. it's researchers summarizing studies that already exist, usually with zero new data. when a "new peptide paper" goes viral, check which one it is first
not every lab name on a COA is a lab you can actually look up. we keep notes on the testing labs that show up most on peptide COAs: https://t.co/L9BAyNdNHb
HPLC and mass spec answer different questions. HPLC: how much of the sample is one compound. mass spec: whether that compound is the one on the label. a COA with only one of them answered half the question